Xilio Therapeutics, Inc.XLONASDAQ
Loading
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | +0.00% | +0.00% | +242.98% | +742.51% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | -407.42% | +727.49% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +130.58% | +134.70% | +167.62% | +17.92% | +127.06% |
| Weighted Average Shares Diluted Growth | +130.58% | +134.70% | +167.62% | +17.92% | +127.06% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | -172.56% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | -174.64% | +0.00% |
| Receivables Growth | +0.00% | +0.00% | -100.00% | +0.00% | +0.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | -4.09% | +16.66% | +25.55% | +48.89% | +79.08% |
| Book Value per Share Growth | -82.67% | -79.64% | -84.48% | -82.06% | +0.00% |
| Debt Growth | -41.78% | -28.93% | -12.08% | -12.92% | -13.69% |
| R&D Expense Growth | -2.64% | -24.71% | -20.52% | +36.68% | +33.11% |
| SG&A Expenses Growth | -0.05% | +9.62% | +38.70% | +22.44% | +0.43% |